Lori J. Wirth, MD, on Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
NCCN 2021 Virtual Annual ConferenceLori J. Wirth, MD, of Massachusetts General Hospital Cancer Center, discusses the common molecular alterations across thyroid cancer subtypes; targeted treatments for BRAF V600E–mutant, NTRK–fusion positive, and RET–altered disease; and optimal therapies for patients with multiple types of thyroid cancer.